Only the loss-of-function but not the gain-of-function properties of mutant TP53 are critical for the sustained proliferation, survival and metastasis of a broad range of cancer cells [breast cancer]

The loss of mutant TP53 did not sensitise tumour cells to chemotherapeutic agents. Overall design: CRISPR/Cas9 was used to delete mutant TP53 a cancer cell line, then responses were detected to the treatment of anticancer drug in the control cells and its mutant TP53 deficient variant.

突变型TP53（mutant TP53）的缺失并未增强肿瘤细胞对化疗药物的敏感性。
实验设计：采用CRISPR/Cas9技术在某癌细胞系中敲除突变型TP53，随后分别检测对照组细胞与该突变型TP53缺失细胞株对抗癌药物处理的响应情况。